Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immune system

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,721 result(s) found for: Immune system. Displaying page 1 of 137.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-000499-41 Sponsor Protocol Number: 1051/04 Start Date*: 2004-12-10
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: mechanisms of endothelial disfunction in patients with les: role of TNF- Alpha
    Medical condition: Lupus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10021428 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000492-18 Sponsor Protocol Number: 1050/04 Start Date*: 2004-12-16
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Insulin resistance and endothelial dysfunction TNF-Alpha dependent in patients with rheumatoid arthritis or metabolic syndrome
    Medical condition: Metabolic Syndrome and Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10021428 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001590-26 Sponsor Protocol Number: MAS QUE NADA Start Date*: 2004-09-15
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: NATIONAL, MULTICENTER, RANDOMIZED,OPEN STUDY TO EVALUATE EFFICACY AND SAFETY OF LAMIVUDINE (300 MG QD) MONOTHERAPY AS AN ALTERNATIVE TO THERAPEUTIC INTERRUPTION IN PAZIENTS AFFECTED BY HIV-1, IN VI...
    Medical condition: HIV MONOTHERAPY TREATMENT , AS THERAPEUTIC MAINTENANCE, DURING INTERRUPTION OF ANTIVIRAL THERAPY
    Disease: Version SOC Term Classification Code Term Level
    6.1 10021428 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005581-37 Sponsor Protocol Number: 5946 Start Date*: 2012-08-06
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Efficacy of Switch to Lopinavir/Ritonavir in Improving Cognitive function in Efavirenz treated patients
    Medical condition: Cognitive function and sleep pattern in HIV-1 patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10021425 Immune system disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001682-41 Sponsor Protocol Number: HLS03/2011 Start Date*: 2011-05-09
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Comparison of the efficacy and the safety of different schedules of administration of sub-lingual immunotherapy in patients with ragweed pollinosis: a phase III randomized and controlled clinical s...
    Medical condition: Subjects who are allergic to Ragweed.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003016-23 Sponsor Protocol Number: CIDAI Start Date*: 2011-05-11
    Sponsor Name:GUNA SPA
    Full Title: Controlled randomized study on maintenance to low activity disease with low doses of SKA citokines compared with standard therapy (DMARDS)of arthritis management
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002257-28 Sponsor Protocol Number: 2021-002257-28 Start Date*: 2021-11-09
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA UDINE
    Full Title: Randomised controlled trial to evaluate the efficacy of local anaesthetic application in spray for the repair of 1st- 2nd perineal lacerations following vaginal delivery
    Medical condition: Considering the high percentage of grade 1 and 2 perineal lacerations, it is evident that another route of administration of the anaesthetic could be of great help in further reducing the discomfor...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-004388-20 Sponsor Protocol Number: 1066/08 Start Date*: 2008-09-19
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: MONOCENTRIC, DOUBLE-BLIND, CASE-CONTROLLED STUDY FOR ASSESSMENT OF PRE-SEASONAL SUBLINGUAL SPECIFIC IMMUNOTHERAPY’S EFFECTIVENESS AS A TREATMENT OF GRASS-INDUCED ALLERGIC RHINOCONJUNCTIVITIS
    Medical condition: ALLERGIC RHINOCONJUNCTIVITIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021428 Immune system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003034-42 Sponsor Protocol Number: ALX0061-C203 Start Date*: 2015-05-08
    Sponsor Name:Ablynx NV
    Full Title: A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis who Have Completed O...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) BG (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008045-38 Sponsor Protocol Number: SS-BEL-01 Start Date*: 2009-06-23
    Sponsor Name:AZIENDA OSPEDALIERA S. MARIA DELLA MISERICORDIA
    Full Title: A Phase 2, proof of concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with primary Sjög...
    Medical condition: Subjects with have a diagnosis of primary SS according to the updated American European Consensus Group Criteria (8). In addition, patients must be always positive for anti-SSA or anti-SSB antibod...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021428 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003033-26 Sponsor Protocol Number: ALX0061-C201 Start Date*: 2015-03-23
    Sponsor Name:Ablynx NV
    Full Title: A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination with Methotrexate, in Subjects with Moderate to...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-003012-36 Sponsor Protocol Number: ALX0061-C202 Start Date*: 2015-03-23
    Sponsor Name:Ablynx NV
    Full Title: A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects with Moderate to Severe Rheumatoid Arthritis who are Intolerant to Methot...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) CZ (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-004078-26 Sponsor Protocol Number: 10/143/FRE Start Date*: 2011-11-30
    Sponsor Name:Brighton & Sussex University Hospitals NHS Trust
    Full Title: A double blind placebo controlled randomised trial to study the effects of birch pollen specific immunotherapy (BP-SIT) on the symptoms of the oral allergy syndrome in adult patients.
    Medical condition: Oral allergy syndrome
    Disease: Version SOC Term Classification Code Term Level
    15.1 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    15.1 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    15.1 10021428 - Immune system disorders 10068355 Oral allergy syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001268-40 Sponsor Protocol Number: HAVEN Start Date*: 2020-01-23
    Sponsor Name:Guy's and St. Thomas' NHS Foundation Trust
    Full Title: Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial
    Medical condition: The term ANCA-associated vasculitis (AAV) describes a subset of primary small vessel vasculitides characterized by the presence of anti-neutrophil cytoplasmic antibodies (ANCA): Granulomatosis with...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-003335-37 Sponsor Protocol Number: 67864238PACRD2001 Start Date*: 2020-06-29
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants with Moderately to Severely Active Crohn’s D...
    Medical condition: Treatment of moderately to severely active Crohn’s disease with JNJ-67864238.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001770-59 Sponsor Protocol Number: BAT-2306-002-CR Start Date*: 2022-10-19
    Sponsor Name:Bio-Thera Solutions, Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2306 with Cosentyx® in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004730-34 Sponsor Protocol Number: 361.11 Start Date*: 2011-07-20
    Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA
    Full Title: A phase II multicentre, randomized, controlled open-label study on the use of anti-thymocyte globulin and rituximab for immunomodulation of graft-versus-host disease in allogeneic matched transpla...
    Medical condition: graft-versus-host disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000196-23 Sponsor Protocol Number: SLO-AD-1 Italy Start Date*: 2008-10-14
    Sponsor Name:ALK-ABELLO'
    Full Title: Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild-to-moderate atopic eczema (AE) and sensitization to HDM (SPT positive).
    Medical condition: Moderate/severe persistent Atopic Eczema (SCORAD >8 and <40)in patients sentitized to HDM
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040785 SOC
    9.1 10038738 SOC
    9.1 10021428 SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000276-23 Sponsor Protocol Number: 201464 Start Date*: 2016-12-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis
    Medical condition: Systemic amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002565-17 Sponsor Protocol Number: WODDOL Start Date*: 2021-12-02
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Multi-center study to evaluate virological efficacy, safety tolerability, drug exposure and patients’ reported outcomes over 48 weeks following randomization to 2-drug therapy with DTG/3TC FDC or c...
    Medical condition: HIV-1-infected adult women of >18 years of age, without previous virologic failure, currently receiving an effective (HIV-RNA < 50 copies/ml) triple-drug cART, containing tenofovir (TAF or TDF) in ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 17:47:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA